Adamed Pharma publishes its 2024 Sustainability Report
Adamed Pharma has published its first voluntary sustainability statement for 2024, prepared on the basis of the European Sustainability Reporting Standards (ESRS). The report covers, among other areas, the company’s environmental impact, its approach to employees and its ethical standards.
The document was prepared in accordance with the double materiality principle and covers the full range of environmental, social, ethical and governance matters. It is one of the first sustainability reports in the Polish pharmaceutical sector prepared on the basis of the ESRS standards resulting from the Corporate Sustainability Reporting Directive (CSRD).
“The document describes key processes and policies, as well as the impacts, risks and opportunities connected with the areas identified as material from the perspective of the Adamed Pharma Group and its stakeholders. Sustainability is becoming increasingly important to business partners, financial institutions and the entire pharmaceutical market,” said Katarzyna Dubno, External Relations, ESG and Health Economics Director at Adamed Pharma.
The company decided to publish the report despite not yet being subject to a regulatory obligation. Under the European Union’s “Stop the Clock” mechanism introduced through the Omnibus Directive, which postponed the application dates of the CSRD requirements, large companies that are not public-interest entities, such as Adamed Pharma, will be required to publish sustainability reports under the Directive only for financial years beginning on 1 January 2027.
The voluntary publication of the Sustainability Report confirms Adamed Pharma’s readiness to operate in an increasingly demanding regulatory environment.
Full report: https://www.adamed.com/_fileserver/item/1508075